TENX
Tenax Therapeutics, Inc.
Price Chart
Latest Quote
$11.87
+0.54 (+4.77%)
Current Price
| Previous Close | $11.33 |
| Open | $11.26 |
| Day High | $11.96 |
| Day Low | $11.26 |
| Volume | 1,278,234 |
Stock Information
| Shares Outstanding | 26.53M |
| Cash Equivalents | $118.75M |
| Net Income | $-57.91M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $318.30M |
| EPS (TTM) | $-1.41 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $156.29M |
| Income | $-57.91M |
| Book/sh | $2.29 |
| Cash/sh | $4.48 |
| Employees | 14 |
Financial Ratios
| Quick Ratio | 13.99 |
| Current Ratio | 14.52 |
Returns & Margins
| ROA | -32.74% |
| ROE | -51.71% |
Ownership
| Insider Ownership | 0.12% |
| Institutional Ownership | 76.25% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -8.51 |
| PEG | 1.44 |
| P/B | 5.24 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $34.00 |
Technical Indicators
| SMA20 | $11.41 |
| SMA50 | $12.47 |
| SMA200 | $11.05 |
| RSI | 51.47 |
| ATR | 0.7067 |
| Shares Float | 10.61M |
| Short Float | 3.02% |
| Short Ratio | 1.36 |
| Rel Volume | 2.50 |
Performance History
| Week | +11.84% |
| Month | +4.58% |
| Quarter | -19.52% |
| 6 Months | +7.53% |
| YTD | +8.60% |
| Year | +111.27% |
| 3 Years | -56.14% |
| 5 Years | -99.64% |
| 10 Years | -99.99% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $12.00 | 2,165,094 |
| 2026-06-17 | $11.87 | 1,280,500 |
| 2026-06-16 | $11.33 | 795,100 |
| 2026-06-15 | $11.55 | 760,000 |
| 2026-06-12 | $11.48 | 1,767,800 |
| 2026-06-11 | $10.73 | 948,700 |
| 2026-06-10 | $10.55 | 381,200 |
| 2026-06-09 | $10.73 | 1,445,800 |
| 2026-06-08 | $10.54 | 587,900 |
| 2026-06-05 | $10.73 | 560,400 |
| 2026-06-04 | $11.09 | 883,600 |
| 2026-06-03 | $10.77 | 554,200 |
| 2026-06-02 | $10.95 | 936,400 |
| 2026-06-01 | $11.97 | 1,700,400 |
| 2026-05-29 | $11.87 | 390,400 |
| 2026-05-28 | $11.69 | 624,100 |
| 2026-05-27 | $11.88 | 497,600 |
| 2026-05-26 | $11.98 | 351,800 |
| 2026-05-22 | $12.13 | 219,600 |
| 2026-05-21 | $12.36 | 443,200 |
| 2026-05-20 | $12.00 | 327,900 |
| 2026-05-19 | $11.48 | 356,500 |
About Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.
đ° Latest News
Companies Like Tenax Therapeutics (NASDAQ:TENX) Are In A Position To Invest In Growth
Simply Wall St. âĸ 2026-04-22T13:20:53Z
DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls
The Fly âĸ 2026-03-17T13:33:56Z
Tenax Therapeutics: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-03-10T11:24:12ZTenax Therapeutics Shares Phase III Levosimendan Progress, H2 Data Timeline at Guggenheim Conference
MarketBeat âĸ 2026-02-15T18:03:52Z
Guggenheim Doubles Tenax (TENX) PT, Names Stock Top Pick
Insider Monkey âĸ 2026-01-08T19:00:35Z
Tenax Therapeutics: Q3 Earnings Snapshot
Associated Press Finance âĸ 2025-11-12T21:17:37ZTenax Therapeutics: Q2 Earnings Snapshot
Associated Press Finance âĸ 2025-08-13T20:17:28Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $0 | $23,000 | $24,000 | $4,443 |
| Total Expenses | $56,385,000 | $19,494,000 | $8,234,000 | $11,052,643 |
| Other Income Expense | $-33,000 | $1,000 | $63,000 | $9,191 |
| Other Non Operating Income Expenses | $-33,000 | $1,000 | $63,000 | $9,191 |
| Net Non Operating Interest Income Expense | $3,819,000 | $1,891,000 | $460,000 | $-4,443 |
| Interest Expense Non Operating | $0 | $23,000 | $24,000 | $4,443 |
| Operating Expense | $56,385,000 | $19,494,000 | $8,234,000 | $11,052,643 |
| General And Administrative Expense | $23,713,000 | $6,785,000 | $5,005,000 | $5,675,231 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-52,599,000 | $-17,602,000 | $-7,711,000 | $-11,047,895 |
| Net Interest Income | $3,819,000 | $1,891,000 | $460,000 | $-4,443 |
| Interest Income | $3,819,000 | $1,914,000 | $484,000 | - |
| Normalized Income | $-52,599,000 | $-17,602,000 | $-7,711,000 | $-11,047,895 |
| Net Income From Continuing And Discontinued Operation | $-52,599,000 | $-17,602,000 | $-7,711,000 | $-11,047,895 |
| Total Operating Income As Reported | $-56,385,000 | $-19,494,000 | $-8,234,000 | $-11,052,643 |
| Net Income Common Stockholders | $-52,599,000 | $-17,602,000 | $-7,711,000 | $-11,047,895 |
| Net Income | $-52,599,000 | $-17,602,000 | $-7,711,000 | $-11,047,895 |
| Net Income Including Noncontrolling Interests | $-52,599,000 | $-17,602,000 | $-7,711,000 | $-11,047,895 |
| Net Income Continuous Operations | $-52,599,000 | $-17,602,000 | $-7,711,000 | $-11,047,895 |
| Pretax Income | $-52,599,000 | $-17,602,000 | $-7,711,000 | $-11,047,895 |
| Interest Income Non Operating | $3,819,000 | $1,914,000 | $484,000 | - |
| Operating Income | $-56,385,000 | $-19,494,000 | $-8,234,000 | $-11,052,643 |
| Per Share | ||||
| Diluted EPS | $-1.34 | $-1.15 | $-31.04 | $-600.71 |
| Basic EPS | $-1.34 | $-1.15 | $-31.04 | $-600.71 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-52,599,000 | $-17,579,000 | $-7,679,000 | $-10,930,120 |
| EBITDA (Bullshit earnings) | $-52,599,000 | $-17,579,000 | $-7,679,000 | $-10,930,120 |
| EBIT | $-52,599,000 | $-17,579,000 | $-7,687,000 | $-11,043,452 |
| Diluted Average Shares | $39,217,244 | $15,271,705 | $248,447 | $18,391 |
| Basic Average Shares | $39,217,244 | $15,271,705 | $248,447 | $18,391 |
| Diluted NI Availto Com Stockholders | $-52,599,000 | $-17,602,000 | $-7,711,000 | $-11,047,895 |
| Research And Development | $32,672,000 | $12,709,000 | $3,229,000 | $5,377,412 |
| Selling General And Administration | $23,713,000 | $6,785,000 | $5,005,000 | $5,675,231 |
| Other Gand A | $6,116,000 | $3,689,000 | $2,828,000 | $3,304,869 |
| Salaries And Wages | $17,597,000 | $3,096,000 | $2,177,000 | $2,370,362 |
| Reconciled Depreciation | - | $0 | $8,000 | $113,332 |
Fetched: 2026-06-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $97,071,000 | $91,993,000 | $8,098,000 | $1,492,741 |
| Total Assets | $104,227,000 | $96,686,000 | $11,685,000 | $3,404,709 |
| Total Non Current Assets | $0 | $0 | $1,000 | $196,244 |
| Current Assets | $104,227,000 | $96,686,000 | $11,684,000 | $3,208,465 |
| Other Current Assets | $1,019,000 | $64,000 | $252,000 | $345,856 |
| Prepaid Assets | $5,643,000 | $1,771,000 | $1,640,000 | $738,927 |
| Cash And Cash Equivalents | $97,565,000 | $94,851,000 | $9,792,000 | $2,123,682 |
| Other Non Current Assets | - | - | $1,000 | $9,552 |
| Cash Cash Equivalents And Short Term Investments | - | - | $9,792,000 | - |
| Debt | ||||
| Total Debt | - | - | $501,000 | $807,891 |
| Long Term Debt And Capital Lease Obligation | - | - | $0 | $64,196 |
| Current Debt And Capital Lease Obligation | - | - | $501,000 | $743,695 |
| Current Debt | - | - | $501,000 | $624,302 |
| Other Current Borrowings | - | - | - | $624,302 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $7,156,000 | $4,693,000 | $3,587,000 | $1,911,968 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $64,196 |
| Current Liabilities | $7,156,000 | $4,693,000 | $3,587,000 | $1,847,772 |
| Payables And Accrued Expenses | $6,258,000 | $3,357,000 | $2,310,000 | $693,816 |
| Payables | $6,041,000 | $3,157,000 | $2,073,000 | $448,425 |
| Accounts Payable | $6,041,000 | $3,157,000 | $2,073,000 | $448,425 |
| Current Notes Payable | - | $0 | $501,000 | $624,302 |
| Other Current Liabilities | - | - | $1,000 | - |
| Equity | ||||
| Common Stock Equity | $97,071,000 | $91,993,000 | $8,098,000 | $1,492,741 |
| Total Equity Gross Minority Interest | $97,071,000 | $91,993,000 | $8,098,000 | $1,492,741 |
| Stockholders Equity | $97,071,000 | $91,993,000 | $8,098,000 | $1,492,741 |
| Retained Earnings | $-367,454,000 | $-314,855,000 | $-297,253,000 | $-289,542,080 |
| Gains Losses Not Affecting Retained Earnings | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $9,314,130 | $3,420,906 | $298,281 | $28,647 |
| Share Issued | $9,314,130 | $3,420,906 | $298,281 | $28,647 |
| Tangible Book Value | $97,071,000 | $91,993,000 | $8,098,000 | $1,492,741 |
| Invested Capital | $97,071,000 | $91,993,000 | $8,599,000 | $2,117,043 |
| Working Capital | $97,071,000 | $91,993,000 | $8,097,000 | $1,360,693 |
| Total Capitalization | $97,071,000 | $91,993,000 | $8,098,000 | $1,492,741 |
| Additional Paid In Capital | $464,524,000 | $406,848,000 | $305,351,000 | $291,034,818 |
| Capital Stock | $1,000 | $0 | $0 | $3 |
| Common Stock | $1,000 | $0 | $0 | $3 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $898,000 | $1,336,000 | $775,000 | $410,261 |
| Current Accrued Expenses | $217,000 | $200,000 | $237,000 | $245,391 |
| Capital Lease Obligations | - | - | $0 | $183,589 |
| Long Term Capital Lease Obligation | - | - | $0 | $64,196 |
| Current Capital Lease Obligation | - | - | $0 | $119,393 |
| Net PPE | - | - | $0 | $186,692 |
| Gross PPE | - | - | $0 | $186,692 |
| Other Properties | - | - | - | $186,692 |
| Other Short Term Investments | - | - | - | - |
Fetched: 2026-06-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-35,800,000 | $-14,811,000 | $-5,904,000 | $-11,390,894 |
| Operating Activities | ||||
| Operating Cash Flow | $-35,800,000 | $-14,811,000 | $-5,904,000 | $-11,388,571 |
| Cash Flow From Continuing Operating Activities | $-35,800,000 | $-14,811,000 | $-5,904,000 | $-11,388,571 |
| Operating Gains Losses | - | - | $1,000 | $362,413 |
| Investing Activities | ||||
| Investing Cash Flow | - | $0 | $3,000 | $-2,323 |
| Cash Flow From Continuing Investing Activities | - | $0 | $3,000 | $-2,323 |
| Capital Expenditure | - | - | - | $-2,323 |
| Financing Activities | ||||
| Financing Cash Flow | $38,514,000 | $99,870,000 | $13,569,000 | $7,930,654 |
| Cash Flow From Continuing Financing Activities | $38,514,000 | $99,870,000 | $13,569,000 | $7,930,654 |
| Issuance Of Capital Stock | - | - | - | - |
| Net Common Stock Issuance | - | - | - | - |
| Common Stock Issuance | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $0 | $-501,000 | $-624,000 | $0 |
| Interest Paid Supplemental Data | $0 | $23,000 | $24,000 | - |
| End Cash Position | $97,565,000 | $94,851,000 | $9,792,000 | $2,123,682 |
| Beginning Cash Position | $94,851,000 | $9,792,000 | $2,124,000 | $5,583,922 |
| Changes In Cash | $2,714,000 | $85,059,000 | $7,668,000 | $-3,460,240 |
| Proceeds From Stock Option Exercised | $38,514,000 | $100,371,000 | $14,193,000 | $7,930,654 |
| Net Issuance Payments Of Debt | $0 | $-501,000 | $-624,000 | $0 |
| Net Short Term Debt Issuance | $0 | $-501,000 | $-624,000 | $0 |
| Short Term Debt Payments | $0 | $-501,000 | $-624,000 | $0 |
| Change In Working Capital | $-2,364,000 | $1,643,000 | $1,583,000 | $-820,864 |
| Change In Payables And Accrued Expense | $2,463,000 | $1,585,000 | $1,889,000 | $-344,951 |
| Change In Accrued Expense | $-421,000 | $523,000 | $237,000 | - |
| Change In Payable | $2,884,000 | $1,062,000 | $1,652,000 | - |
| Change In Account Payable | $2,884,000 | $1,062,000 | $1,652,000 | - |
| Change In Prepaid Assets | $-4,827,000 | $58,000 | - | - |
| Stock Based Compensation | $19,163,000 | $1,125,000 | $191,000 | - |
| Net Income From Continuing Operations | $-52,599,000 | $-17,602,000 | $-7,711,000 | $-11,047,895 |
| Net PPE Purchase And Sale | - | $0 | $3,000 | $-2,323 |
| Sale Of PPE | - | $0 | $3,000 | - |
| Change In Receivables | - | $58,000 | $-306,000 | $-356,520 |
| Changes In Account Receivables | - | $58,000 | $-306,000 | $-356,520 |
| Other Non Cash Items | - | $23,000 | $24,000 | $4,443 |
| Depreciation Amortization Depletion | - | $0 | $8,000 | $113,332 |
| Depreciation And Amortization | - | $0 | $8,000 | $113,332 |
| Gain Loss On Sale Of PPE | - | $0 | $1,000 | $-2,901 |
| Change In Other Current Liabilities | - | - | $0 | $-119,393 |
| Depreciation | - | - | $7,570 | $113,332 |
| Gain Loss On Investment Securities | - | - | $190,850 | $365,314 |
| Issuance Of Debt | - | - | - | $624,302 |
| Short Term Debt Issuance | - | - | - | $624,302 |
| Net Investment Purchase And Sale | - | - | - | $0 |
| Sale Of Investment | - | - | - | $0 |
| Purchase Of Investment | - | - | - | $0 |
| Purchase Of PPE | - | - | - | $-2,323 |
| Amortization Of Securities | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
Fetched: 2026-06-15